Learning Hub Central
Breast
2025 MaTOS Breast | Response Predictors for Breast Cancer Immunotherapy
Breast
Non-CME Credit Course
2025 MaTOS Breast | Bispecific/Biparatopic Antibodies in Breast Cancer (Zanidatimab, PM8002, etc)
Breast
Non-CME Credit Course
2025 MaTOS Breast | Therapeutic and Preventive Vaccines for Triple Negative Breast Cancer
Breast
Non-CME Credit Course
2025 MaTOS Breast | Innate immune Signaling in Breast Cancer
Breast
Non-CME Credit Course
2025 MaTOS Breast | Next Generation in Targeting DNA Repair
Breast
Non-CME Credit Course
2025 MaTOS Breast | ADCs: Other Novel Targets and Pathways
Breast
Non-CME Credit Course
2025 MaTOS Breast | Antibody Drug Conjugates (ADCS) to Enhance Anti-Tumor Immune Response
Breast
Non-CME Credit Course
2025 MaTOS Breast | PI3K/AKT: Choices, Sequencing and New Agents
Breast
Non-CME Credit Course
2025 MaTOS Breast | Novel Endocrine Therapies
Breast
Non-CME Credit Course
2025 MaTOS Breast | Who Needs Radiation Post Neoadjuvant Therapy
Breast
Non-CME Credit Course
2025 MaTOS Breast | Evaluating and Targeting Defects in DNA Repair
Breast
Non-CME Credit Course
2025 MaTOS Breast | Innovation in Tackling Triple Negative Residual Disease Following Preoperative KN-522 Regimen
Breast
Non-CME Credit Course
2025 MaTOS Breast | Strategies to Treat High Risk HR+, HER2 - Residual Disease (CDKi, IO, ADCs?)
Breast
Non-CME Credit Course
2025 MaTOS Breast | Improving and Optimizing Adjuvant Treatment for HER2+ Residual Disease
Breast
Non-CME Credit Course
2025 MaTOS Breast | Neoadjuvant with Antibody Drug Conjugates (ADC)
Breast
Non-CME Credit Course
2025 MaTOS Breast | Neoadjuvant Immunotherapy for HR+ Disease
Breast
Non-CME Credit Course
2025 MaTOS Breast | Neoadjuvant Immunotherapy for Triple Negative Breast Cancer
Breast
Non-CME Credit Course
2025 MaTOS Breast | Neoadjuvant Endocrine Therapy
Breast
Non-CME Credit Course
2025 MaTOS Breast | Understanding Mechanisms of ADC Resistance: Lessons Learned and New Directions
Breast
Non-CME Credit Course
2025 MaTOS Breast | Multi-Cancer Early Detection (MCED)
Breast
Non-CME Credit Course
2025 MaTOS Breast | The Integrative Breast Cancer Subtypes: From Relapse Prediction to Novel Targets
Breast
Non-CME Credit Course
2025 MaTOS Breast | Use of Artificial Intelligence in Breast Cancer Diagnostics
Breast
Non-CME Credit Course
2025 MaTOS Breast | Exosomes in Diagnosis and Treatment
Breast
Non-CME Credit Course
2025 MaTOS Breast | Proteomics: The Promise for the Future
Breast
Non-CME Credit Course
2025 MaTOS Breast | ctDNA (Liquid Biopsy for MRD) in the Curative Setting
Breast
Non-CME Credit Course
2025 MaTOS Breast | ctDNA Biomarkers to Drive Therapy
Breast
Non-CME Credit Course
2025 MaTOS Breast | A Primer on ctDNA Technologies
Breast
Non-CME Credit Course
2025 WCS | Immunotherapy for Breast Cancer
Breast
Non-CME Credit Course
2024 NOSCM | Applying New Endocrine and Targeted Agents to the Treatment of Hormone Receptor Positive, HER2 Negative Breast Cancer
Breast
Non-CME Credit Course
2025 WCS | HER-2 Disease: From NeoAdjuvant to Metastatic Setting
Breast
Non-CME Credit Course
2024 NOSCM | Antibody Drug Conjugates for HER2 Negative Breast Cancer: A Revolution in Chemotherapy for Breast Cancer
Breast
Non-CME Credit Course
2025 PRIMO | Immunotherapy and Optimal Chemotherapy for Early Stage TNBC: When and in Whom?
Breast
Non-CME Credit Course
2025 PRIMO | New Directions In Chemotherapy and Immunotherapy for HR+ Breast Cancer
Breast
Non-CME Credit Course
2025 PRIMO | Advances in the Treatment of HER2+ Breast Cancer
Breast
Non-CME Credit Course
2025 PRIMO | Major Endocrine and Targeted Therapy Advances In the Treatment of HR+/HER2- Breast Cancer
Breast
Non-CME Credit Course
2021 AIO | Recent Advances in Breast Cancer
Breast
Non-CME Credit Course
2023 CCC | HER2 Targeted Therapies: Recent Advances
Breast
Non-CME Credit Course
2023 CCC | New Biomarkers in Breast Cancer
Breast
Non-CME Credit Course
2023 CCC | Hormone Therapy in Breast Cancer: New Directions
Breast
Non-CME Credit Course
2024 Locally Advanced NSCLC: Neoadjuvant/Adjuvant/Multi-Modality
Breast
Non-CME Credit Course
2025 MCM | Understanding Germline Testing: When? Who? And What is Next?
Breast
Non-CME Credit Course
2024 NOSCM | Immunotherapy for Breast Cancer: Efficacy and Toxicity Considerations
Breast
Non-CME Credit Course
2025 MCM | New and Evolving Directions in the Treatment of HER2 Positive Breast Cancer
Breast
Non-CME Credit Course
2024 MLS Irvine | Localized Breast Cancer Updates
Breast
Non-CME Credit Course
2024 MLS Irvine | Metastatic ER Positive Breast Cancer Updates in 2024
Breast
Non-CME Credit Course
2024 MLS Irvine | Metastatic HER2 Positive Breast Cancer Updates in 2024
Breast
Non-CME Credit Course
2024 BCS | CNS METS- Evolving Multidisciplinary Tumor Board Conversations Radiation Oncology
Breast
Non-CME Credit Course
2024 BCS | CNS METS- Evolving Multidisciplinary Tumor Board Conversations Medical Oncology
Breast
Non-CME Credit Course
2024 BCS | Immunotherapy: Wait, Why Wait
Breast
Non-CME Credit Course
2024 BCS | Keynote Lecture: Genetics and RACE
Breast
Non-CME Credit Course
2024 BCS | The Art of Medicine in the Clinic
Breast
Non-CME Credit Course
2024 BCS | Metastatic HER2neu Positive Breast Cancer
Breast
Non-CME Credit Course
2024 BCS | Post-Op Decision Making
Breast
Non-CME Credit Course
2024 BCS | Neoadjuvant Candidacy and Treatment
Breast
Non-CME Credit Course
2024 BCS | Stage 1A – De-Escalation v Escalation
Breast
Non-CME Credit Course
2024 BCS | HER2 LOW Advanced and Metastatic Breast Cancer | How Low Do You Go?
Breast
Non-CME Credit Course
2024 BCS | HER Family Transmembrane Proteins & BRCA | An Old Story Turns a New Corner
Breast
Non-CME Credit Course
2024 BCS | Metastatic Interrogations and Recommendations
Breast
Non-CME Credit Course
2024 BCS | Neoadjuvant Updates
Breast
Non-CME Credit Course
2024 BCS | Stage 1A TNBC: Treatment and Outcomes
Breast
Non-CME Credit Course
2024 BCS | Cell Cycle and Immune Check Point Inhibitors | Research, Clinic, Patient
Breast
Non-CME Credit Course
2024 BCS | Breast Cancer Recurrence Risk & Lifestyle Modifications
Breast
Non-CME Credit Course
2024 BCS | Maturity of the Patient and evolving treatment options
Breast
Non-CME Credit Course
2024 BCS | HR Positive Metastatic Breast Cancer - Are there Forks in the Road?
Breast
Non-CME Credit Course
2024 BCS | Neoadjuvant and Adjuvant Approaches
Breast
Non-CME Credit Course
2024 BCS | ILC, When Non-scary Becomes Scary
Breast
Non-CME Credit Course
2024 BCS | Antibody Drug Conjugates Expanding a Targeted Assault on all Breast Cancer Subtypes
Breast
Non-CME Credit Course
2024 BCS | Breast Cancer Screening – Updates in Research and liquid Biopsy
Breast
Non-CME Credit Course
2024 BCS | Breast Cancer Screening – Updates in Breast Imaging
Breast
Non-CME Credit Course
2024 BCS | Escalation
Breast
Non-CME Credit Course
2024 BCS | De-Escalation
Breast
Non-CME Credit Course
2024 BCS | LCIS and ILC – Old Story with New Concerns
Breast
Non-CME Credit Course
2024 BCS | Breast Cancer – Transgender Construction and Deconstruction
Breast
Non-CME Credit Course
2024 BCS | Denovo Metastatic Breast and the Role of Surgery
Breast
Non-CME Credit Course
2024 BCS | Post Neoadjuvant Chemotherapy and the Axilla
Breast
Non-CME Credit Course
2024 NOSCM | Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (NO)
Breast
Non-CME Credit Course
2024 NOSCM | Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (YES)
Breast
Non-CME Credit Course
HER2 Positive Breast Cancer Updates in 2024
Breast
Non-CME Credit Course
ER Positive Breast Cancer Updates in 2024
Breast
Non-CME Credit Course
Controversies in Breast Cancer: Use of ctDNA to Tailor Systemic Adjuvant / Post-neoadjuvant Therapies (Part 1)
Breast
Non-CME Credit Course
2024 MCM | Immunotherapy in Breast Cancer: Now & The Future
Breast
Non-CME Credit Course
HER-2 Disease: Amplification / Overexpression / Mutation in Breast Cancer
Breast
Non-CME Credit Course
2024 MCM | Triple Negative Breast Cancer: Optimal Strategies
Breast
Non-CME Credit Course
2024 MCM | Endocrine Therapy for Early -and Late- Stages Breast Cancer: Therapeutic Updates
Breast
Non-CME Credit Course
2024 MLS Cleveland | HER2 Targeted Updates in Breast Cancer
Breast
Non-CME Credit Course
2024 MLS New Orleans | Master Lecture on Triple Negative Breast Cancer
Breast
Non-CME Credit Course
2024 MLS New Orleans | Master Lecture on Endocrine Therapy in Early/Advanced Breast Cancer
Breast
Non-CME Credit Course
2024 MLS New Orleans | Master Lecture on HER-2 in Breast Cancer
Breast
Non-CME Credit Course
2024 PRIMO | Advances in the Treatment of High Risk Early Stage Hormone Receptor Positive Breast Cancer
Breast
Non-CME Credit Course
Antibody Drug Conjugates- New Directions, New Agents!
Breast
Non-CME Credit Course
2024 PRIMO | Sequencing Endocrine Therapy And Targeted Agents For The Treatment Of Hormone Receptor Positive Metastatic Breast Cancer
Breast
Non-CME Credit Course
Breast Cancer Update in Hormone Sensitive Breast Cancer
Breast
Non-CME Credit Course
2023 UCT | New Developments in Metastatic Breast Cancer: Immunotherapy and Novel Therapeutic Pathways
Breast
Non-CME Credit Course
2024 SPECTRUM | Transcatheter treatment in breast cancer
Breast
Non-CME Credit Course
2024 SPECTRUM | Ablation in Benign & Malignant Breast Disease
Breast
Non-CME Credit Course
2024 SPECTRUM | Role of Radiation in breast cancer
Breast
Non-CME Credit Course
2024 SPECTRUM | Advances in the systemic management of breast cancer
Breast
Non-CME Credit Course
2024 SPECTRUM | Surgical management in breast cancer
Breast
Non-CME Credit Course
Triple Negative Breast Cancer
Breast
Non-CME Credit Course
2022 MLS Denver | HER2 Breast Cancer
Breast
Non-CME Credit Course
2022 MLS Denver | Hormone Receptor Breast Cancer
Breast
Non-CME Credit Course
New Agents and New Applications of Targeted Therapy For Hormone Receptor Positive Breast Cancer
Breast
Non-CME Credit Course
Endocrine Therapy for Early-Stage Breast Cancer: Who Needs More?
Breast
Non-CME Credit Course
Locally Advanced NSCLC (Neoadjuvant/Adjuvant Therapies)
Breast
Non-CME Credit Course
2021 UCT | New Developments in Therapeutics for Metastatic Breast Cancer
Breast
Non-CME Credit Course
2022 MLS New Orleans | Targeted Therapy in Breast Cancer Beyond ER/PR
Breast
Non-CME Credit Course
2022 MLS New Orleans | Immunotherapy in Breast Cancer
Breast
Non-CME Credit Course
Advanced Breast Cancer: State of the Art
Breast
Non-CME Credit Course
Adjuvant Therapy in Breast Cancer: State of the Art
Breast
Non-CME Credit Course
2022 NOSCM | Sequencing Therapy in Early Stage TNBC: Reducing and Increasing the Intensity of Therapy
Breast
Non-CME Credit Course
2022 NOSCM | Immunotherapy for Triple Negative Breast Cancer
Breast
Non-CME Credit Course
2022 NOSCM | Antibody Drug Conjugated for Breast Cancer: Current Therapy and New Directions
Breast
Non-CME Credit Course
2022 MLS Nashville | Breast Cancer Update in HER2 Breast Cancers
Breast
Non-CME Credit Course
2022 MLS Nashville | Breast Cancer Update in Triple Negative Breast Cancer
Breast
Non-CME Credit Course
2022 MCM | CDK4/6, PIK3CA & PARP Inhibitors in MBCA
Breast
Non-CME Credit Course
2022 MCM | Endocrine Therapy in the Neoadjuvant & Adjuvant Setting
Breast
Non-CME Credit Course
HER2-Driven Breast Cancer: Current Status and Next Generation Therapeutics
Breast
Non-CME Credit Course
Breast Cancer Immunotherapy
Breast
Non-CME Credit Course
2021 NOSCM | Immunotherapy in Metastatic Breast Cancer
Breast
Non-CME Credit Course
PI3K and CDK4/6 Strategies: Efficacy Data and Management of Toxicity
Breast
Non-CME Credit Course
2021 NOSCM | Updates on Adjuvant, Neoadjuvant & Metastatic Settings in HER2+ Breast Cancer
Breast
Non-CME Credit Course
2021 NOSCM | Endocrine Therapy in Non-Metastatic Breast Cancer Setting
Breast
Non-CME Credit Course
2021 NOSCM | Bench Lab Advances for Breast Cancer
Breast
Non-CME Credit Course
2021 MCM | Breast Cancer Session
Breast
Non-CME Credit Course
Breast Targeted Therapy - HER2, CDK 4-6, PI3KCA
Breast
Non-CME Credit Course
Immunotherapy in Breast
Breast
Non-CME Credit Course
Breast Cancer Update in Triple Negative and HER2 Breast Cancers
Breast
Non-CME Credit Course
2021 CCC | Advances in Metastatic Breast Cancer
Breast
Non-CME Credit Course
2021 CCC | Advances in HER2 Positive Metastatic Breast Cancer
Breast
Non-CME Credit Course
2022 MLS San Francisco | Update in Management of TNBC
Breast
Non-CME Credit Course
2022 MLS San Francisco | New Development in HER2+ Breast Cancer
Breast
Non-CME Credit Course
2022 MLS San Francisco | Current Practice and Future Developments in HR+ Breast Cancer
Breast
Non-CME Credit Course
Neoadjuvant & Adjuvant Therapy for Breast Cancer
Breast
Non-CME Credit Course
Hormonal Therapy for Metastatic Breast Cancer
Breast
Non-CME Credit Course
Predictive and Prognostic Biomarkers: Using Genomic Profile in Adjuvant Breast Cancer
Breast
Non-CME Credit Course
Contact Us
